Passage Bio
$24.989876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$24.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$2.33 (-8.53%) As of 4:00 PM UTC today
Why Robinhood?
You can buy or sell Passage Bio and other stocks, options, and ETFs commission-free!
About PASG
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA. The listed name for PASG is Passage Bio, Inc. Common Stock.
CEO
Bruce A. Goldsmith
Employees
20
Headquarters
Philadelphia, Pennsylvania
Founded
2017
Market Cap
1.09B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
237.90K
High Today
$27.12
Low Today
$24.37
Open Price
$27.11
Volume
205.22K
52 Week High
$38.23
52 Week Low
$8.09
Collections
PASG Earnings
-$1.00
-$0.67
-$0.33
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 23, Pre-Market